key: cord-0857805-jza0eq7s
authors: Wolfe, Cameron; Humar, Atul
title: Buyer beware: The risks of donor‐derived vaccine‐induced thrombosis and thrombocytopenia
date: 2021-08-25
journal: Am J Transplant
DOI: 10.1111/ajt.16802
sha: 9ba3d81496b3224f6328d02f1a4b04e0a7ae2553
doc_id: 857805
cord_uid: jza0eq7s

The emergence of the Sars-CoV-2 virus has posed unique challenges specific to transplantation and donation. For our transplant patients on our waiting lists, they have faced uncertainty, unsure if the pandemic will delay live-saving transplants. In March 2021, Vaccine-Induced Thrombosis and Thrombocytopenia (VITT) and central venous sinus thrombosis was recognized, first in Europe with the Astra-Zeneca ChAdOx01 nCoV-19 vaccine, and then in the United States with the Janssen Covid-19 Ad.26.COV2.S vaccine. Not only did this represent a new risk to describe to our patients and colleagues, but because of the life-threatening nature of this complication, we began receiving offers from donors who had died from VITT (1,2) .

There are no published case reports of transplant programs using organ donors with VITT secondary to the Janssen vaccine, which has been the adenovirus vector vaccine used in the United States. In

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Updated recommendations from the Advisory Committee on Immunization Practices for use of the Janssen (Johnson & Johnson) COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients-United States

Organ transplantation from deceased donors with vaccine-induced thrombosis and thrombocytopenia

Solid organ procurement and transplantation from deceased donors with vaccineinduced thrombosis and thrombocytopenia

Antibody epitopes in vaccine-induced immune thrombotic thrombocytopenia

Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination

Therapeutic Goods Administration. COVID-19 vaccine weekly safety report -06-05-2021 [Internet, last viewed on